Patrick Mahaffy - Mar 1, 2022 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
President and Chief Executive Officer, Director
Signature
/s/ Patrick Mahaffy
Stock symbol
CLVS
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:15 PM
Previous filing
Nov 19, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Stock Option (right to buy) Award $0 +220K $0.00 220K Mar 1, 2022 Common Stock 220K $1.95 Direct F1
transaction CLVS Stock Option (right to buy) Award $0 +80K $0.00 80K Mar 1, 2022 Common Stock 80K $1.95 Direct F2
transaction CLVS Stock Option (right to buy) Award $0 +80K $0.00 80K Mar 1, 2022 Common Stock 80K $1.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
F2 The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021.
F3 The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024.

Remarks:

President and Chief Executive Officer